We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Phytopharm | PYM | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 58.00 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 58.00 | 58.00 |
| Top Posts |
|---|
Posted at 21/5/2013 08:26 by greedfear Investors in PYM do not lose their investment. If you find this difficult to understand than you could compare this to PYM buying (the shares of) an another company and paying with PYM shares.{I like it. The new company (PYM + the other) keep the cash, are revenue generating while PYM tax losses can still be carry forward (provided the new shareholders in the new company hold less than 25%)} |
Posted at 07/4/2013 07:33 by moneymunch Healthcare Investment Opportunities joins AIM05/04/2013 Harriet Russell HIO has started trading as a public company Investment scouter Healthcare Investment Opportunities (LON:HIO) has joined London's junior market this morning. The company completed an additional placing along with the float of 40 million shares at a price of 10p per share, raising gross proceeds worth £4 million. The market capitalisation of the company is expected to be approximately £4.1 million. The funds raised will be used for working capital whilst the Board seek suitable investments and, where applicable, acquisitions in line with the Company's Investment Policy. The board has said it intends to use the proceeds for working capital needs as well as for any upcoming acquisitions deemed useful for the company. The first acquisition will be likely to be a reverse takeover but will be subject to shareholder approval and is expected to be made within six months of admission. In addition, the board may also consider making other smaller acquisitions or investments although the directors have said they do not intend to create a portfolio of 'unconnected companies'. The board as a whole, and in particular chairman David Evans are said to have an extensive contact base and a proven record of creating value for investors through building businesses in the healthcare sector via a combination of organic and acquisitive growth. Examples include Axis Shield, BBI Holdings, DxS, EKF Diagnostics Holdings, Epistem Holdings, Scancell Holdings and Sirigen Group. Shares were trading at 11.3p today. |
Posted at 18/2/2013 09:30 by genises Mr Tim Sharpington was very upbeat in his last statement,Knowing the results were due he should had delayed his previous statement.looks as if someone as a large investor new what the results were going to be from the large sales in the past few days???? |
Posted at 14/2/2013 10:53 by mrsapeslaptop RNS looks like Henderson global investors have reduced their stake |
Posted at 11/2/2013 21:40 by gnomet2 Dr Biotech 11 Feb'13 - 12:41 - 369 of 371 0 0I'm a bit wary about results on monkeys, particularly PD tests. With PD monkeys you chemically kill the dopamine genration with MPTP to produce the PD effects. Its not true PD and any drugs that may restore life to the dopamine area may not work in humans as the original cause of PD may remain and counter and effect the drug has. There have been quite a few successful treatments of MPTP monkeys that have failed in trials. Still fingers crossed. Sure the monkeys don't actually have the disease and underlying causes , but fortunately (for investors) I'm sure the results won't need to be anything like as good as the monkey ones to be successful. I reckon just a 10 -20% improvement over any placebo score will be sufficient. (EDIT In terms of showing a statistically significant difference and a clinically meaningful one). I'd expect the commercial and regulatory performance bars to be set lower than risky and expensive gene therapy treatments. I think the failures after good monkey results have all? been with gene therapies tested on patients both with long term disease and L-dopa exposure, causing big alterations in brain chemistry and damage/ spasticity at the synapses through intense irregular neuronal firing induced by L-Dopa admin. It was notable that a sub-group of monkeys treated with OXB's Prosavin performed only half as well when pretreated with L-Dopa just for a couple of months. Cogane is being tested on earlier stage and L-Dopa naïve patients, so I think there's reason to think they might fare better at reproducing the monkey results.. |
Posted at 15/1/2013 01:29 by mrsapeslaptop hmmmmmmm.really dunno. shareholder base very unusual here. an institution and 300 people who have more than a grand. its a binary bet on results in Feb. insider trading enforcement is much tougher than year ago. Ive looked at the obvious reasons for hedging/ shorting and find none. so no clues investors await results in Feb. |
Posted at 19/12/2012 15:32 by mrsapeslaptop annual report out. no surprises.last page interesting. There are only 300 investors who have more than a grands worth of shares. no wonder its quiet on here (at the moment) |
Posted at 18/12/2012 07:10 by tez123 Phytopharm PLCCogane in ALS Update RNS Number : 7480T Phytopharm PLC 18 December 2012 18th December 2012 COGANE IN ALS UPDATE Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", the "Group", or the "Company") today announces an update on plans for the further clinical development of CoganeTM as a potential treatment for Amyotrophic Lateral Sclerosis ("ALS"). Earlier this year the Company announced the successful completion of the preclinical evaluation of Cogane in ALS, which provided strong support for progression into clinical trials in this indication. Subsequently the Company has been working with a number of leading opinion leaders and charities with an interest in ALS to design a clinical development plan for Cogane in ALS. As part of this process two leading grant-giving bodies, the ALS Association ("ALSA") and the North-East ALS Consortium ("NEALS") in conjunction with Massachusetts General Hospital, have provisionally indicated that they will provide financial and logistic support for future studies of Cogane in ALS. Both of these grants are contingent on the Company moving forward with a study in ALS. The Company is also in discussion with leading regulatory agencies with regard to the design of a clinical development plan for Cogane in ALS. Cogane has been granted orphan drug designation for the treatment of ALS in both the US and Europe. Orphan drug designation provides a number of research and development as well as financial advantages to companies developing products targeting the relatively uncommon conditions labelled as "orphan". In parallel with this work, Phytopharm has been completing a 400-patient, Phase II trial of Cogane in early-stage Parkinson's disease (CONFIDENT-PD). All patients have now completed the trial and the Company is on-track to receive the results from this trial in February 2013 as previously announced. The Company will determine the best way forward for Cogane in both Parkinson's disease and ALS once it has analysed the results from the CONFIDENT-PD trial. Tim Sharpington, Phytopharm CEO, commented "We believe that the pre-clinical data received earlier this year provide a clear rationale for moving forward with clinical trials with Cogane in ALS. We are pleased to have received strong support for this programme from leading experts and charities in the field and are working to finalise our development plans with regulatory agencies. "Whilst the progression of the ALS programme is not wholly dependent on the outcome of the CONFIDENT-PD trial for CoganeTM in Parkinson's Disease, its results may inform the design and conduct of future studies in this setting. We continue to eagerly await the results from this important phase II trial which are expected in February, before making definitive decisions on how best to proceed in both indications, be that alone or in partnership with other companies." Notes to Editors Enquiries Phytopharm plc Tim Sharpington, CEO +441480 437697 Roger Hickling, R&D Director +44 1480 437697 U.K. Investor Relations FTI Consulting Limited Ben Atwell John Dineen +44 207 831 3113 Phytopharm plc Phytopharm plc ("Phytopharm") is a development stage pharmaceutical company developing novel treatments targeting diseases with high levels of unmet need. Our lead series of compounds, the sapogenins (including Cogane and Myogane), has the potential to be a new class of therapy for neurodegenerative diseases including Parkinson's disease (PD), amyotrophic lateral sclerosis ("ALS") and glaucoma. Phytopharm operates as a virtual company ensuring the majority of our financial resources are focused on our pharmaceutical pipeline. We utilise a network of external scientific and clinical experts to help guide our development projects with our experienced pharmaceutical managers overseeing operations. Our commercially focused development projects have the potential to produce significant treatment advances in our target areas of neurodegeneration and inflammatory disease. Our products are single chemical entities with novel mechanisms of action protected by strong patent families. Our pipeline has been sourced from our own research activities and from licensing activities, particularly from leading research institutions in China with whom the Company has long-standing relationships. Our objective is to develop products aimed at major markets with high unmet medical need to key value inflection points before seeking late-stage development and commercial partners as appropriate. Phytopharm is listed on the premium segment of the Official List of the FSA and traded on the main market of the London Stock Exchange. Further information on Phytopharm is available from the Company's website www.phytopharm.com About Cogane Phytopharm's lead development candidate is Cogane, a member of the sapogenin class of compounds. It is an orally bioavailable neurotrophic factor modulator that readily crosses the blood‑brain barrier. Cogane has demonstrated neuroprotective effects in a range of preclinical models of neurodegenerative diseases. Specifically, CoganeTM has been shown to induce and modulate the production of neurotrophic factors. The neuroprotective and neurotrophic actions of Cogane suggest potential beneficial effects in a range of neurodegenerative diseases, including ALS and Parkinson's disease. Cogane has completed long term toxicology studies, has been formulated as a once daily, orally administered therapy and has completed Phase I studies demonstrating a good bioavailability and safety profile. In addition to the preclinical programme in ALS, Cogane is being studied in an ongoing 28 week Phase II clinical trial of patients with early stage Parkinson's disease (CONFIDENT‑PD) Cogane has been granted Orphan Drug status by both the European Commission and by the US Food & Drug Administration for development in ALS and this will allow significant access to the regulatory authorities for advice and expedited clinical progression as well as providing financial advantages. About amyotrophic lateral sclerosis (ALS) ALS, also known as Lou Gehrig's disease, is the most prevalent form of motor neurone disease, which generally strikes people between 40 and 60 years of age. It is estimated that there are over 400,000 patients living with ALS globally. It is a neurodegenerative disease with limited treatment options and poor prognosis. It is characterised by progressive loss of both lower (spinal cord and brain stem) and upper (cerebral cortex) motor neurones, which leads to severe muscle weakness and wasting, followed by paralysis and death, generally caused by respiratory failure. There is an urgent need for the development of new approaches to this devastating condition. About Orphan Drug Designation For a product to gain orphan drug status in the United States, the clinical condition must affect less than 200,000 people in the United States. If a product has been granted orphan drug status, FDA will provide assistance in the design of the preclinical and clinical studies needed to achieve marketing approval for the designated clinical condition. Additionally, there are financial incentives available (such as waiver of the fee for the marketing application, currently over $1.5M) and 7 years' market exclusivity (compared to 5 years available for non‑orphan diseases). |
Posted at 23/6/2011 23:00 by mrsapeslaptop I'm disappointed with the lack of PI interest. but aftera all its gone from 600p to 6p. but IMHO prospects are actually better than ever before.I had thought of this bcompnayeing 50p ish. but if it works in multiple indications then could be a £1bn + company (500p ish). oh well. thats the joy of being a contrarian investor |
Posted at 29/11/2010 21:25 by bengal1 coupled with an investors presentation |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
